scholarly journals Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE)

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259389
Author(s):  
Yutaka Kawahito ◽  
Yuya Takakubo ◽  
Akio Morinobu ◽  
Naoko Matsubara ◽  
Orsolya Nagy ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Combination Therapy ◽  
Treatment Adherence ◽  
Treatment Satisfaction ◽  
Work Productivity ◽  
Japanese Patients ◽  
Oral Medication ◽  
Total Work ◽  
Global Satisfaction

Objective To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with poorly controlled rheumatoid arthritis (RA) treated with conventional synthetic, targeted synthetic, or biologic disease-modifying antirheumatic drugs (DMARDs), we conducted a subgroup (post hoc) analysis of Japanese patients participating in the SENSE study. Methods Data for Japanese patients (n/N = 118/1629) from the global, multicenter, cross-sectional, observational SENSE study were analyzed. The primary endpoint was the global satisfaction subscore assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Other patient-reported outcomes included self-reported RA medication adherence and Work Productivity and Activity Impairment-RA. Patient perspectives included patients’ expectations and preference of pharmacologic treatment. Results Median (range) age and RA disease duration were 67.0 (18.0–87.0) years and 8 (0.0-54) years, respectively; 81.4% of patients were female. Mean (SD) TSQM global satisfaction subscore was 56.8 (17.5), and only 5.9% of patients reported good satisfaction with treatment (TSQM global ≥80). Mean (SD) self-reported treatment adherence using VAS was high (93.5% [13.8%]). Mean (SD) total work productivity impairment was 45.6% (32.0%); presenteeism contributed toward more total work productivity impairment (43.9% [30.4%]) than absenteeism (8.3% [24.4%]). Patients expected improvement in all parameters from their treatment, especially improvement in joint symptoms. Most patients (80.7%) preferred oral medication and 18.7% preferred monotherapy. Patient acceptability of potentially manageable side effects was high (7.5%-34.0%). Although most patients (81.3%) found combination therapy acceptable, 43.2% were receiving DMARD monotherapy. Conclusion Although most Japanese patients with RA with moderate-to-high disease activity were dissatisfied with their current DMARD treatment, high treatment adherence, high acceptability of combination therapy, high acceptability of manageable potential side effects, and preference for oral medication were reported. Data support the development of a more individualized and patient-centric approach for RA treatment.

The side-effects and efficacy of leflunomide in Japanese patients with rheumatoid arthritis

2005 ◽  
Vol 8 (2) ◽  
pp. 114-118 ◽  
Author(s):  
Katsuaki KANBE ◽  
Kazuhiko INOUE ◽  
Junji CHIBA ◽  
Masahiko NOGUCHI ◽  
Yoriko HIGUCHI ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Japanese Patients

scholarly journals Analysis of treatment satisfaction and adherence among patients with type 2 diabetes

2020 ◽  
Vol 48 (7) ◽  
pp. 476-486
Author(s):  
M. F. Kalashnikova ◽  
I. B. Bondareva ◽  
N. V. Likhodey ◽  
Yu. P. Sych
Keyword(s):  
Type 2 Diabetes ◽  
Side Effects ◽  
Treatment Adherence ◽  
Treatment Satisfaction ◽  
Patient Questionnaire ◽  
Comprehensive Treatment ◽  
Free Access ◽  
High Treatment

Background: Low treatment adherence in patients with type 2 diabetes mellitus (T2DM) hinders the effective use of anti-diabetic agents and the achievement of glycemic control, reducing their quality of life and outcomes. Assessment of treatment adherence can help to identify and manage factors and barriers that affect therapy and treatment satisfaction.Aim: To assess the treatment adherence of patients with T2DM, to identify the main barriers to adherence, and patient satisfaction with the treatment.Materials and methods: FORSIGHT-T2DM was a  Russian multiregional, multicenter observational epidemiological study in 2014 patients with T2DM. The patients were assessed with the FORSIGHT- T2DM Patient Questionnaire, Moriski Medication Adherence Scale (MMAS), and Diabetes Treatment Satisfaction Questionnaire (DTSQ).Results: The mean (± SD) treatment adherence estimated using the MMAS was 5.86±1.39 points. The main barriers to adherence were high treatment costs, medication side effects, forgetfulness when taking drugs, complexity of the therapy or treatment regimen. The average number of daily medications was four. There was also a lack of contact with a doctor, poor awareness of the disease and its complications. Ninety (90) per cent of the respondents trusted the recommendations from their doctors, 7.6% followed the advice of relatives or friends. The patient's choice of medication was influenced by information about its effectiveness, its cost, and reimbursement, ease of administration, and information on the absence of side effects. Seventy eight (78) per cent of the respondents were “completely” or “rather” satisfied with their treatment. About 15% of patients rated the quality of care as unsatisfactory.Conclusion: The results of the study identified an intermediate level of treatment adherence in most patients with T2DM, as well as multiple adherence barriers, including comorbidities and the need for continuous intake of various agents. Most patients showed high treatment satisfaction, which could be due to the high availability of outpatient consultations by an endocrinologist and inpatient treatment, free access to anti-diabetic medications. However, it may also be a  result of biased assessment of problems due to insufficient patient awareness of the therapy goals and a low level of knowledge about their disease. To study the factors affecting the adherence to medical recommendations among patients with T2DM, it is necessary to develop a  specific questionnaire for this patient category, which would allow for an evaluation both drug intake and other aspects of their comprehensive treatment, including the identification and analysis of the main barriers to adherence.

scholarly journals Satisfaction with medication in coronary disease treatment: psychometrics of the Treatment Satisfaction Questionnaire for Medication

2016 ◽  
Vol 24 (0) ◽  
Author(s):  
Ana Carolina Sauer Liberato ◽  
Roberta Cunha Matheus Rodrigues ◽  
Thaís Moreira São-João ◽  
Neusa Maria Costa Alexandre ◽  
Maria Cecília Bueno Jayme Gallani
Keyword(s):  
Side Effects ◽  
Construct Validity ◽  
Treatment Satisfaction ◽  
Reliability And Validity ◽  
University Hospital ◽  
Southeastern Brazil ◽  
Floor Effect ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction ◽  
Convergent Construct Validity

Abstract Objective: to psychometrically test the Brazilian version of the Treatment Satisfaction Questionnaire for Medication - TSQM (version 1.4), regarding ceiling and floor effect, practicability, acceptability, reliability and validity. Methods: participants with coronary heart disease (n=190) were recruited from an outpatient cardiology clinic at a university hospital in Southeastern Brazil and interviewed to evaluate their satisfaction with medication using the TSQM (version 1.4) and adherence using the Morisky Self-Reported Measure of Medication Adherence Scale and proportion of adherence. The Ceiling and Floor effect were analyzed considering the 15% worst and best possible TSQM scores; Practicability was assessed by time spent during TSQM interviews; Acceptability by proportion of unanswered items and participants who answered all items; Reliability through the Cronbach's alpha coefficient and Validity through the convergent construct validity between the TSQM and the adherence measures. Results: TSQM was easily applied. Ceiling effect was found in the side effects domain and floor effect in the side effects and global satisfaction domains. Evidence of reliability was close to satisfied in all domains. The convergent construct validity was partially supported. Conclusions: the Brazilian TSQM presents evidence of acceptability and practicability, although its validity was weakly supported and adequate internal consistency was observed for one domain.

Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa

Dermatology ◽  
2021 ◽  
pp. 1-4
Author(s):  
Alexandre Docampo-Simón ◽  
Iván Beltrá-Picó ◽  
María José Sánchez-Pujol ◽  
Rosa Fuster-Ruiz-de-Apodaca ◽  
Juan Selva-Otaolaurruchi ◽  
...  
Keyword(s):  
Side Effects ◽  
Treatment Satisfaction ◽  
Hidradenitis Suppurativa ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction ◽  
The Mean ◽  
High Treatment

<b><i>Background:</i></b> Topical 15% resorcinol is commonly used in clinical practice for the treatment of nodules and abscesses in patients with hidradenitis suppurativa (HS). It has been shown to be clinically effective in some small studies, but data on satisfaction perceived by patients are lacking. The Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is a validated measure of patient satisfaction, evaluating four domains: effectiveness, side effects, convenience, and global satisfaction. Our objective was to obtain data from HS patients regarding resorcinol treatment satisfaction and its relationship with clinical and epidemiological variables. <b><i>Methods:</i></b> We performed a cross-sectional study providing TSQM version 1.4 questionnaires to HS patients who had been prescribed topical resorcinol during the previous 24 months. <b><i>Results:</i></b> Ninety-two patients answered the questionnaire. Eighty-five out of 92 (92.4%) were Hurley II and 7 Hurley I. The mean total score was 317.5 out of 400 (71.0 points in effectiveness, 93.6 in side effects, 79.3 in convenience, and 73.2 in global satisfaction). Total score was higher in men than in women (329.7 vs. 311.6, <i>p</i> = 0.026) and higher scores on convenience were seen in patients who were not overweight or obese (86.9 vs. 77.1, <i>p</i> = 0.016). Most patients (65, 70.6%) denied having any side effect. 78 (84.8%) of the patients would recommend the treatment. <b><i>Conclusion:</i></b> The results of this study suggest that HS patients treated with resorcinol 15% are very satisfied with this treatment.

Association Between Adherence to Statins, Illness Perception, Treatment Satisfaction, and Quality of Life among Lebanese patients

2018 ◽  
Vol 23 (5) ◽  
pp. 414-422 ◽  
Author(s):  
Christine Haddad ◽  
Souheil Hallit ◽  
Mohammad Salhab ◽  
Aline Hajj ◽  
Antoine Sarkis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Marital Status ◽  
Treatment Adherence ◽  
Educational Level ◽  
Treatment Satisfaction ◽  
Illness Perception ◽  
Global Satisfaction ◽  
Adherence Score ◽  
The Mean

Objectives: The main objective of this study was to evaluate treatment adherence to statin and health-related quality of life (QOL) in Lebanese patients with dyslipidemia. Secondary objectives were to examine associations between treatment adherence, QOL, treatment satisfaction, and illness perception. Methods: This cross-sectional study, conducted in 20 community pharmacies from all districts of Lebanon between August 2016 and April 2017, enrolled 247 adult patients taking any statin. Results: The mean age of the participants was 52.63 ± 11.92 years (57.5% males); the mean duration of treatment with a statin was 59.72 months. A significant association was found between adherence and marital status ( P < .0001), educational level ( P = .001), cigarette smoking ( P < .0001), and alcohol drinking ( P < .0001). A negative but significant correlation was found between the adherence score and the duration of dyslipidemia ( r = −0.199). A significant but negative correlation was also found between the side effect score and age ( r = −0.137). The monthly salary, the marital status, the educational level, smoking cigarettes or waterpipes, and drinking alcohol were all associated with the Illness Perception Questionnaire scores ( P < 0.0001 for all variables). Secondary level of education (β = 13.43), smoking more than 3 waterpipes per week (β = 14.06), global satisfaction score (β = 0.32), convenience score (β = 0.29), and effectiveness score (β = 0.27) would significantly increase the adherence score. Smoking more than 15 cigarettes per day (β = −11.15) and a divorced status (β = −14.81) would however significantly decrease the adherence score. Significant associations were found between the illness perception score, the QOL domains, and the satisfaction domains ( P < .05 for all variables). Conclusion: This study showed that global satisfaction with treatment, convenience, and effectiveness are important factors that increase treatment adherence. Patient adherence results in patient satisfaction and improved QOL and is an important criterion for achieving desired therapeutic outcomes.

scholarly journals Treatment satisfaction for gene silencing pharmacotherapies for the treatment of hereditary transthyretin amyloidosis with polyneuropathy

2021 ◽  
Author(s):  
Deilys Gonzalez ◽  
Duncan Brown ◽  
Montserrat Vera Llonch ◽  
Aaron Yarlas ◽  
Kristen McCausland ◽  
...  
Keyword(s):  
Side Effects ◽  
Gene Silencing ◽  
Treatment Satisfaction ◽  
Online Survey ◽  
The United States ◽  
Transthyretin Amyloidosis ◽  
Global Satisfaction ◽  
Treatment Groups ◽  
Scale Scores ◽  
Hereditary Transthyretin Amyloidosis

Background and Aims: Hereditary transthyretin amyloidosis (hATTR) is a rare, progressive, systemic, fatal condition in which misfolded transthyretin proteins form amyloid in tissues and organs, often manifesting in polyneuropathy (hATTR-PN). The FDA has approved 2 gene-silencing pharmacotherapies for hATTR-PN: inotersen, administered subcutaneously; and patisiran, administered intravenously. Patient satisfaction for each treatment was examined during a period overlapping with the COVID-19 pandemic. Methods: Patients with hATTR-PN (with and without accompanying cardiomyopathy) in the United States participated in an observational, online survey between January 1 and October 25, 2020. The Treatment Satisfaction Questionnaire for Medication, version II (TSQMvII), was administered to 29 patients currently being treated with inotersen (n=11) or patisiran (n=18). TSQMvII produces 4 scale scores—Effectiveness, Side Effects, Convenience, and Global Satisfaction—ranging from 0 to 100. Higher scores indicate greater satisfaction. TSQMvII scores were descriptively compared between treatment groups. Results: Patients receiving inotersen indicated greater satisfaction with convenience than patients receiving patisiran (mean, 76.3 [SD=19.4] vs 58.6 [15.3], respectively), and less dissatisfaction with treatment side effects (86.1 [16.4] vs 68.3 [19.0]). Ratings were comparable between treatments with respect to effectiveness (72.0 [21.5] vs 67.1 [19.7]) and global satisfaction (78.0 [20.0] vs 74.5 [21.7]). Conclusions: While inotersen and patisiran were rated similarly in effectiveness and overall treatment satisfaction, inotersen was associated with less dissatisfaction with side effects and greater convenience, with the latter possibly reflecting differences in mode of administration (ie, at home vs visit to a clinical site), which may be particularly important during a pandemic.

Sign in / Sign up

Export Citation Format

Share Document